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Abstract
Mitochondrial dynamics play an important role in cellular homeostasis and a variety of human diseases are linked to its
dysregulated function. Here, we describe a 15-year-old boy with a novel disease caused by altered mitochondrial dynamics.
The patient was the second child of consanguineous Jewish parents. He developed progressive muscle weakness and
exercise intolerance at 6 years of age. His muscle biopsy revealed mitochondrial myopathy with numerous ragged red and
cytochrome c oxidase (COX) negative fibers and combined respiratory chain complex I and IV deficiency. MtDNA copy
number was elevated and no deletions of the mtDNA were detected in muscle DNA. Whole exome sequencing identified a
homozygous nonsense mutation (p.Q92*) in the MIEF2 gene encoding the mitochondrial dynamics protein of 49 kDa (MID49).
Immunoblotting revealed increased levels of proteins promoting mitochondrial fusion (MFN2, OPA1) and decreased levels of
the fission protein DRP1. Fibroblasts of the patient showed elongated mitochondria, and significantly higher frequency of
fusion events, mtDNA abundance and aberrant mitochondrial cristae ultrastructure, compared with controls. Thus, our data
suggest that mutations in MIEF2 result in imbalanced mitochondrial dynamics and a combined respiratory chain enzyme
defect in skeletal muscle, leading to mitochondrial myopathy.
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Introduction
Mitochondria are essential organelles for maintaining cellular
energy production in the form of ATP through oxidative phosphor-
ylation (OXPHOS) and they play a role in the fundamental physio-
logical cellular processes such as energy balance, modulation of
calcium signaling, cellular redox and the normal function of many
significant biosynthetic pathways (1). Mitochondria are constantly
re-shaping organelles that move along cytoskeletal tracks, under-
going fusion and fission events to build interconnected networks,
assisting the cell to adapt to its ever-changing physiological
condition (2).
In skeletal muscle, mitochondria play key roles in metabolic
regulation, fiber type specificity and intracellular calcium
homeostasis (3). Diverse mitochondrial pathologies have been
linked to skeletal muscle dysfunction and mutations in mito-
chondrial dynamics proteins lead to variable mitochondrial dis-
eases affecting the nervous system and skeletal muscle.
Patients carrying mutations affecting the inner mitochondrial
membrane fusion protein, OPA1, associated with Autosomal
Dominant Optical Atrophy (ADOA), are characterized by early-
onset blindness and develop late-onset myopathy (4) and
altered muscle mitochondrial ATP synthesis (5). In addition,
mutations affecting the outer mitochondrial membrane (OMM)
fusion protein, MFN2, are associated with autosomal dominant
axonal Charcot-Marie-Tooth Type 2 (CMT2) neuropathy (6–7).
Patients carrying MFN2 mutations associated with CMT2 also
develop late onset myopathy (8), suggesting that altered mito-
chondrial dynamics compromises the organelle’s function espe-
cially in neuronal cells and in skeletal muscle.
Mitochondrial fission requires the recruitment of a large
GTPase to the OMM from the cytosol, called dynamin-related
protein 1 (DRP1). DRP1 exists as dimer or tetramer in the cytosol
and when it binds to the OMM assembles into higher-ordered
complexes requiring GTP hydrolysis (9–11), and this directs its
constriction and scission (12–13).
In mammals, three adaptors (MFF, MID49 and MID51) recruit
DRP1 to the OMM. Recruitment of DRP1 to the OMM is signifi-
cantly reduced in MFF-null cells, indicating that MFF is essential
to mitochondrial fission (14–15). Recent studies have suggested
that MID49 and MID51, which are encoded by the genes MIEF2
(SMCR7) and MIEF1 (SMCR7L), respectively, act as receptors of
DRP1. The genes encoding MID49 and MID51 are paralogues to
each other sharing 45% of sequence identity (16) and differen-
tially expressed in tissues during different developmental
stages (17). Both proteins are anchored in the OMM and can
recruit DRP1 independently to MFF and FIS1 (16,18). Finally,
MID49 and MID51 are specific mitochondrial adaptors of DRP1
in contrast to MFF and FIS1 which are also present in peroxi-
somes (18).
Here we report a patient with mitochondrial myopathy due
to a homozygous mutation in MID49 (MIEF2, SMCR7) with com-
bined respiratory chain enzyme defect and augmented mito-
chondrial fusion in the patients skeletal muscle and fibroblasts.
Results
Clinical presentation
The 15-year-old boy is the second child of consanguineous
Jewish parents. The older sister is healthy. At the age of 6 years
he first presented with progressive muscle weakness, intermit-
tent muscle pain and exercise intolerance. Creatine kinase (CK)
activity in serum was elevated (1283 U/l, normal< 170 U/l).
At that time, a brain MRI was performed with unremarkable
results, and dystrophinopathy was excluded genetically by
MLPA. Pompe’s disease was excluded by enzymatic testing of
alpha glucosidase activity in dried blood spots. Within the fol-
lowing years he received regular physiotherapy, but his
muscular symptoms aggravated. At the age of 10 years he first
presented to our centre for further diagnostics. He was able to
walk about 200 meters and to climb about 10 steps without a
break. Ophthalmological examination was repeatedly normal,
EMG has not been performed because the reflexes were normal
and there was no clinical sign of neuropathy.
Clinical investigation revealed a proximal muscle weakness
without any signs of other organ involvement. The CK level was
again elevated (760 U/l, normal< 217 U/l). Cardiologic evaluation
was normal. A muscle biopsy was performed and revealed a
mitochondrial myopathy. A metabolic screening including
organic acids in urine and acylcarnitines in dried blood spots
was performed, but showed a normal pattern and did not indi-
cate multiple acyl-CoA dehydrogenase deficiency (MADD).
The patient was started on riboflavin (100 mg/day p. o.) and
coenzyme Q10 (120 mg/day). Physiotherapeutic treatment was
continued once per week. Under this regimen both muscle pain
as well as muscle strength improved (walking range 800 meters,
2–3 stairs, cycling 12 kilometers). During follow up CK levels var-
ied between 377 and 1996 U/l (normal< 247 U/l).
Muscle biopsy analysis
Muscle biopsy revealed mitochondrial myopathy with numer-
ous ragged red fibres (data not-shown) and COX negative fibres
(Fig. 1A). In addition, the muscle fibres showed heterogeneous
staining intensity of NADH dehydrogenase indicative of aber-
rant mitochondrial function in certain fibres (low blue) and ele-
vated mitochondrial mass in small, likely regenerative fibres
(dark blue) (Fig. 1B). Biochemical measurement showed defi-
ciencies of multiple respiratory chain enzymes (Fig. 1E and F).
Molecular genetic studies
Diagnostic testing excluded mutations and deletions of the
mtDNA and no depletion was detected, rather mtDNA copy
number was three times higher than the control in skeletal
muscle. WES identified a homozygous stop mutation in the
MIEF2 gene (NM_148886) (c.274C>T, p.Q92*), encoding the mito-
chondrial elongation factor 2, MID49. Sanger sequencing was
undertaken to validate the variants and confirm that these seg-
regated with the disease in the family (Fig. 1C). This mutation is
predicted to be pathogenic, because it results in a premature
stop leading to loss of the MID49 protein (Fig. 1D). The variant is
very rare and is not found in ExAC or gnomAD. The patient also
carries a homozygous likely benign (class 2 after the classifica-
tion of the American College of Medical Genetics and Genomics)
ETFA mutation (c.20C>T, p.P7L). It has been seen in ExAc in 9
out of 15 286 cases in heterozygous state. Mutations in ETFA
cause multiple acyl-CoA dehydrogenase deficiency (MADD),
however metabolic screening in the patient revealed no MADD-
typical pattern and lipid accumulation was also absent in
muscle excluding this diagnosis.
Quantitative PCR for detecting mRNA of MIEF2 and MIEF1 in
the patients fibroblasts showed severe reduction of MIEF2
mRNA, suggesting nonsense-mediated decay, while MIEF1
(MID51) was not significantly altered (Fig. 3D).
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Biochemical respiratory chain enzyme analysis and
immunoblotting in skeletal muscle
Biochemical measurement showed deficiencies of multiple res-
piratory chain enzymes (Fig. 1E). Subunits of complexes I, II, III
and IV were significantly decreased in the patient’s skeletal
muscle, once normalized by mitochondrial mass content that
showed elevation, estimated by VDAC1 relative levels. Complex
V protein levels did not change significantly (Fig. 2A).
MID49 protein in the muscle biopsy of the patient showed
significantly decreased levels, when compared with controls
(Fig. 2B). Based on our sequencing studies, a total absence of the
MID49 band was expected. As MID49 and MID51 share 45%
homology, it is possible that the polyclonal antibody is detecting
some MID51 in this patient’s lysate.
Given the relevance of MID49 in the maintenance of mito-
chondrial dynamics, we evaluated the protein levels of MFN2,
OPA1, DRP1 and MID51 in total protein lysates extracted from
the patient’s and controls’ skeletal muscle. These data revealed
significant increases in the relative levels of MFN2 (P¼ 0.002,
unpaired t-test) and OPA1 (P¼ 0.02, unpaired t-test). DRP1 levels
were significantly decreased (P¼ 0.0005, unpaired t-test) in
the patient’s skeletal muscle, while MID51 was significantly
increased in the same tissue (Fig. 2C). Thus, these data suggest
that both fusion and fission proteins adapt in the patient to
compensate the absence of MID49.
Mitochondrial functional studies in fibroblasts
To investigate functional effects of the MIEF2 (MID49) variant,
primary fibroblasts from the patient and control subjects were
analysed. Oxygen consumption of the patient fibroblasts (repre-
sentative of three biological replicates) showed a slight increase
in basal respiration rate (22% increase) compared with the con-
trol fibroblasts whilst the levels of maximal respiration were
slightly decreased (3% decrease) compared with controls
(Fig. 3A). These results were not statistically significant.
Elevated protein levels were detected in all OXPHOS complexes
(Fig. 3B), as measured by immunoblotting. A significant increase
was observed in the relative protein levels of CII and CIV
(P¼ 0.02, P¼ 0.016 respectively, unpaired t-test).
Relative mtDNA copy number was measured in DNA
extracted from the patient’s fibroblasts and controls. MtDNA
copy number was significantly increased (P¼ 0.01, unpaired
t-test) in the patient when compared with control (Fig. 3C).
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in relaon to grams of Non-
Collagen Protein  [U/g NPC]
in relaon to citrate synthase 
[Quoent]
Complex I 13.0 U/g NPC 15.8 – 42.8 0.13 0.17 – 0.56
Complex II/III 13.5 U/g NPC 6.0 – 25.0 0.13 0.08 – 0.45
Complex IV 67.5 U/g NPC 112 - 351 0.66 1.1 – 5.0
Citrate 
synthase(CS)
102.2 U/g NPC
Non-Collagen 
Protein (NCP)
6.3 g/l
Parameter Acvity Reference range
in relaon to grams of Non-Collagen Protein  [U/g NPC]
Coenzyme Q10 259.1 nmol/g NPC 160 - 1200
Coenzyme Q10/CS 2.6 nmol/ U/g NPC 2.7 – 7.0
Citrate synthase (CS 97.9 U/g NPC
Non-Collagen Protein 
(NCP)
6.8 g/l
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F
Figure 1. Diagnostic testing of respiratory chain function in skeletal muscle and genetic studies. (A) Simultaneous staining of muscle fibres for cytochrome oxidase
(COX) and succinate dehydrogenase (SDH), (B) Nicotinamide adenine dinucleotide (NADH) staining of muscle fibres. Dark blue muscle fibres represent increased mito-
chondrial proliferation, pale muscle fibres illustrate deficient muscle fibres. (C) Pedigree diagram and Sanger sequencing results showing the segregation of the MIEF2
c.274C>T, p.Q92* mutation. (D) Schematic showing MIEF2 gene structure, MID49 wildtype protein structure [domains represented as follows: Mitochondrial
Intermembrane (MtIM), Helical (H), Cytoplasmic and Mab21] and MID49 mutant p.Q92* structure including conservational analyses of the amino acid among species.
(E) Biochemical measurement of respiratory chain enzymes. (F) Coenzyme Q10 in the muscle biopsy of the patient. Abnormal values are marked in bold.
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To further demonstrate the depletion of MID49 we per-
formed immunoblotting, detecting significantly decreased pro-
tein expression levels (P¼ 0.01, unpaired t-test) of MID49 in the
patient’s fibroblasts when compared with two control cell lines
(Supplementary Material, Fig. S1A). These results are represen-
tative of three biological replicates. Immunoblotting for
enriched mitochondrial fraction from the patient and control
fibroblasts also showed depletion of the MID49 protein (data not
shown).
We measured the proteins involved in mitochondrial fusion
and fission, including MFN2, OPA1, DRP1 and MID51 in whole
protein lysate isolated from the patient’s fibroblasts and com-
pared with controls. The patient showed a slightly decreased
level of DRP1 and MID51 protein compared with control fibro-
blasts. A slight increase in expression of MFN2 and OPA1 was
observed in the patient, when compared with controls, but this
was not significant. The results are representative of three bio-
logical replicates (Supplementary Material, Fig. S1B).
In vivomitochondrial continuity and fusion analysis
Next, we evaluated the dynamics of mitochondria, testing con-
tinuity and fusion frequency. Fibroblasts of the patient with the
MID49 mutations and controls were transiently transfected to
express mitochondrial matrix-targeting fluorescent proteins
mtDsRed and photoswitchable protein mtPA-GFP, and tested by
in vivo confocal microscopy. Mitochondrial morphology of
MID49 p.Q92* cells showed elongated pattern (Fig. 4A, left
panel), consistent with a decrease in fission protein MID49. In
addition, we tested mitochondrial continuity and fusion events
frequency by photoactivation of mtPA-GFP within confined
regions of interest (ROI, 25 lm2), and followed the diffusion of
the photoswitched protein, towards the vicinity of the ROI
(Fig. 4B). As expected, mitochondrial continuity, measured as
the decay of mtPA-GFP fluorescence intensity in the ROIs, aug-
mented in the MID49 p.Q92* carrying cells, and else, the fusion
events frequency was significantly elevated in these cells. Thus,
the morphology and connectivity of mitochondria are increased
in MID49 p.Q92* carrying cells, likely consistent with an
impaired fission phenotype. In addition, fusion of mitochondria
is also induced, suggesting a compensatory effect to keep mito-
chondrial quality control.
To further confirm that the hyperfused mitochondrial pat-
tern is caused by the absence of MID49 and not by an unrelated
adaptive response, we rescued MID49 by exogenous expression
of human MID49 (hMID49-GFP) in the patient’s fibroblasts
(Supplementary Material, Fig. S2A). Our data show that hMID49-
GFP shifted the hyperfused mitochondrial phenotype observed
in the patient, to intermediate and semi-connected mitochon-
dria population, comparable to mitochondrial morphology in
control cells (Supplementary Material, Fig. S2B). In addition, we
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Figure 2. Mitochondrial function in skeletal muscle. (A) Immunoblot analysis of OXPHOS complex subunits performed on total protein lysate from skeletal muscle of
the patient (p.Q92*) and controls (n¼3). (B) Immunoblotting detected significantly decreased expression of MID49 protein in the patients skeletal muscle when com-
pared with controls (n¼3). (C) Quantification of MFN2, OPA1, DRP1 and MID51 protein levels from total protein lysates extracted from muscle biopsies of the patient
and controls (n¼3).
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performed fluorescence recovery after photobleaching (FRAP)
experiments to study mitochondrial continuity, which is known
to be supported by mitochondrial fusion and motility. We found
that rescue of hMID49 in the patient’s cells showed a significant
decrease in the FRAP kinetics, again comparable to control
cells (Supplementary Material, Fig. S2C and D). Expression of
hMID49-GFP did not alter mitochondrial morphology or con-
tinuity in control human fibroblasts. Thus, our findings show
that mitochondrial dynamics defects presented in MID49 p.Q92*
carrying fibroblasts are a consequence of the absence of the pro-
tein and not of unrelated causes, confirming the pathogenicity
of the mutation.
Ultrastructure studies
To evaluate the ultrastructure of mitochondria from control and
patient’s fibroblasts, we performed TEM studies (Fig. 5).
We measured the area of mitochondria, finding no significant dif-
ferences between control and MID49 p.Q92* mutant cells, yet, the
distribution of mitochondrial areas frequency showed increased
proportion of groups of organelles within 0.44–0.74 lm2, that are
among the largest groups, Figure 5B. This is consistent with the
morphology changes observed by confocal fluorescence micro-
scopy. In terms of the organelle’s membrane ultrastructure, mito-
chondria from control cells showed structured, regular and
deeply folded cristae. Strikingly, the MID49 mutant cells displayed
elevated percentage of irregular cristae, consisting of short and
discontinuous folding throughout a mitochondrion’s matrix with
clear or empty areas, as well as a group of empty mitochondria,
significantly increased, compared with control cells. Thus, the
absence of MID49 in mitochondria results in an elevated popula-
tion of organelles showing aberrant mitochondrial cristae organi-
zation, yet, based on our functional data, this pattern does not
significantly alter overall mitochondrial function in fibroblasts.
Discussion
One of the unique characteristics of mitochondria is their ability
to build large interconnected and intracellular networks via
fusion and fission (19). These two balanced activities determine
the mitochondrial morphology and distribution. DRP1 oligomer-
izes around the mitochondrion and plays a major role in mito-
chondrial fission by directing this process. However, it is still
unclear how DRP1 is recruited to the mitochondrial surface.
To date, four different adaptors have been suggested to act as
mediators of DRP1 recruitment; initially FIS-1and MFF and
recently MID49 and MID51 (19). Mutations in DRP1 lead to sev-
eral serious neurological disorders including epileptic encephal-
opathy (20–23) and optic atrophy (24), A truncating mutation in
MFF was first described in a Saudi Arabian child with develop-
mental delay, pyramidal signs, and neuropathy. The mutation
removes the transmembrane domain in MFF which abolishes
the mitochondrial function resulting in a phenotype consistent
with lack of fission (25). Finally, patients carrying MFF-loss of
function variants present encephalopathy, optic atrophy and
peripheral neuropathy (26).
Here, we describe a patient with a homozygous nonsense
mutation in the gene encoding MID49. Although most mito-
chondrial fusion/fission related diseases affect the nervous sys-
tem (optic atrophy, peripheral neuropathy), the phenotype of
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Figure 3. Mitochondrial functional studies in patient fibroblasts. (A) Oxygen consumption in fibroblasts carrying the homozygous nonsense mutation c.274C>T, p.Q92*
in MIEF2 (MID49). Black and grey bars represent the mean values of control and patient’s primary fibroblast cells respectively. The corrected oxygen consumption by
the non-mitochondrial respiration (NMR) is represented as basal respiration, leaking respiration and maximal respiration. These data are representative of three differ-
ent biological replicates. (B) Immunoblot analysis of OXPHOS complex subunits performed on total protein lysate of fibroblasts from the patient and controls (n¼3).
(C) Quantification of the relative mtDNA copy number shows a significant increase in the patient’s fibroblasts when compared with controls. (n¼3). (D) Quantitative
PCR of MIEF1 and MIEF2 mRNA in control (black bars) and patient (grey bars) fibroblasts (n¼3). The graphs represent relative fold change in gene expression to house-
keeping genes GAPDH and b-Actin.
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our patient is an isolated mitochondrial myopathy and does not
affect optic and peripheral nerves or any other organs.
The patient had a myopathy with increased CK, suggesting a
metabolic myopathy, however, the muscle biopsy revealed
severe mitochondrial changes with numerous ragged red fibres
and COX negative fibres. Elevated CK is unusual in other forms
of mitochondrial myopathies except for TK2 deficiency and
therefore it may be an important hallmark of this disease.
The homozygous stop mutation (c.274C>T, p.Q92*) in MIEF2
results in reduced protein levels of MID49 although some resid-
ual protein was still detected in immunoblot analysis in
the patient’s skeletal muscle. Different antibodies targeting
the MID49 protein were used in immunoblotting, however, the
results were the same (data not shown). It is hypothesized that
either the mutation allows some read-through, or the antibod-
ies used for the detection of MID49 might not be strictly specific
for this protein and may detect the MID51 protein due to their
sequence similarity.
The defect in MID49 resulted in a muscle-specific mitochon-
drial dysfunction. Interestingly, in adult human skeletal
muscle, MIEF2 mRNA shows significant elevation, with regards
to MIEF1, suggesting a relevance for this fission anchor in
muscle (17). In this work, we detected reduced activities of the
mitochondrial respiratory chain complexes I and IV and immu-
noblotting showed lower levels of multiple complexes and
subunits in skeletal muscle. The several ragged red fibres and
the increased mtDNA copy number and mitochondrial house-
keeping protein mass indicated compensatory mitochondrial
proliferation. The significantly increased levels of proteins
involved in mitochondrial fusion (MFN2 and OPA1) and signifi-
cantly decreased levels of DRP1 expression in skeletal muscle
suggest that reduced levels of MID49 result in imbalanced
mitochondrial dynamics. Significantly increased protein
expression of MFN2 and OPA1 in patient muscle illustrates
overexpression of proteins responsible for mitochondrial fusion
at the OMM. Importantly, elevated levels of OPA1 are associated
with aberrant mitochondrial morphology in cells (27), suggest-
ing that this adaptive response in the muscle might be detri-
mental to mitochondrial morphology and function quality. On
the other hand, DRP1 protein levels were significantly
decreased in the same tissue suggesting limited mitochondrial
fission activity. Although previous studies have shown that loss
of MID49 in mouse embryonic fibroblast (MEF) cells does not
affect the levels of MID51 (28), we show significantly increased
levels of MID51 in the skeletal muscle of our MID49 deficient
patient. MID49 and MID51 crystal structures show both similar-
ities and differences. Although both MID49 and MID51 contain a
nucleotidyl transferase domain, only MID51 is able to bind
nucleotide diphosphates (ADP and GDP) whereas MID49 is
believed to bind an unknown ligand. MID51 is dimeric in con-
trast to MID49 which is monomeric but both share motifs inter-
acting with DRP1. Their structural differences might suggest a
differential regulation and stabilization of MID51 versus MID49
(29–31).
Although we detected significant changes in respiratory
chain function in skeletal muscle only, a milder involvement of
Figure 4. Mitochondrial continuity and fusion are elevated in human mutant fibroblasts (MID49 p.Q92*). (A) Cells were transfected with mtDsRed and mtPA-GFP codify-
ing plasmids and images by confocal microscopy. Representative cells before and after photoactivation of 5x5 regions interest (ROIs: white squares). The images dis-
play the continuity among mitochondria evidenced by the diffusion of photoconverted PA-GFP towards neighbouring mitochondrial out of ROIs. (B) mtPA-GFP
fluorescence decay evaluated inside the photoactivation area. Grey curves, individual regions; black curves represent the mean. (C) Frequency of fusion events. n¼ 29
Control and 24 Patient cells. Data from at least four independent experiments.
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respiratory chain function was also present in the patient’s
fibroblasts as shown by the increased oxidative phosphoryla-
tion in the patients fibroblasts. Based on these data, the
increased mtDNA copy number in fibroblasts accompanied with
increased relative expression of the protein complexes of the
respiratory chain and no significant mitochondrial dysfunction
might indicate a possible adaptive mechanism in fibroblasts.
Interestingly, we have previously demonstrated increased
mtDNA levels in blood cells from Charcot Marie Tooth 2A
patients, carrying MFN2 mutations (32). In support of the dys-
functional MID49 in fibroblasts, we detected elongated mito-
chondria and significantly increased fusion events when
compared with controls. This is in accordance with previous
reports showing that the absence or downregulation of MID49
leads to and hyper-elongated mitochondrial pattern (15–16,18),
however, it is the first report demonstrating that mitochondrial
fusion frequency is elevated when MID49 is absent. The
increased fusion events in the fibroblasts carrying the homozy-
gous nonsense mutation were accompanied by slight increase
of OPA1 and MFN2 protein levels, that might account for the
elevated fusion activity. These data are consistent with pre-
vious publications where knockdown of MID49 in either COS or
Hela cells resulted in increased levels of OPA1 (16). In addition,
the elongation pattern displayed upon MID49 overexpression
relay on the co-expression of MFN1 and MFN2 in MEF cells (18).
Interestingly, the elongated mitochondrial pattern observed in
MID49 or MID51 knock out cells has been linked to the recruit-
ment of an inactive phosphorylated form of DRP1 at Ser-637
(15). Our data show no change in the overall protein levels of
DRP1 in the patient’s cells, which is in agreement with previous
observations (16,18). Yet, based on our data and the literature,
additional mechanisms might be supporting the mitochondrial
elongated phenotype, such as co-transcriptional regulation of
both groups of fusion and fission proteins, or stabilization of
MID51 and mitofusins or OPA1 once inserted in the correspond-
ing mitochondrial membranes. Importantly, we demonstrate
here that rescuing of MID49 protein levels recover mitochon-
drial morphology and dynamics, confirming that the c.274C>T,
p.Q92* mutation causes the abnormal mitochondrial hyperfu-
sion phenotype.
Figure 5. Mitochondrial ultrastructure in control and patient (p.Q92* in MIEF2) fibroblasts. (A) Cells were pelleted and fixed with glutaraldehyde 2%. The data show a
population of normal mitochondria in control cells, displaying regular shape and cristae (left-hand panel). MIEF2 p.Q92* fibroblasts show a diverse pattern, including
elongated and mitochondria carrying aberrant cristae with total or partial absence of cristae (red arrows). The images are representative of 2 independent experiments.
(B) Mitochondrial area frequency distribution, indicating an increased population of enlarged mitochondria (n¼at least 250 mitochondria/condition). (C) Mitochondrial
cristae were classified as: structured (showing regularly presented, deeply folded), irregular, aberrant and empty (absence of cristae).
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Finally, although the absence of MID49 did not compromise
the patient’s fibroblasts oxidative performance, the ultrastruc-
ture of mitochondrial cristae showed alterations in terms of
abundance and depth, displaying a significant increase of aber-
rant mitochondria. Conversely, studies in MID49/51 double
knock-out cells showed no change in mitochondrial ultrastruc-
ture, and prevented ultrastructure re-arrangement induced by
an apoptotic stimulus (33). The patient’s fibroblasts show
severely reduced MID49 protein, comparable MID51 levels and
only a mild increase in Opa1, in comparison to control cells,
thus, the ultrastructure changes cannot be attributed to imbal-
anced fusion fission proteins, but presumably to the perturba-
tion of cristae junction regulatory pathways. Also, based on the
latter, the compensatory elevation of mtDNA levels stands a
possible mechanism to adapt to disorganization of IMM folding,
known to host OXPHOS complexes (34).
In conclusion, c.274C>T, p.Q92* in MID49 is the first reported
mutation in this new adaptors of DRP1 linked to human disease.
These findings emphasize the vital role of MID49 in mitochon-
drial dynamics, which predominantly affects mitochondrial
function in skeletal muscle and displays an adaptive phenotype
in fibroblasts. Our data provide new insights to the relevance of
mitochondrial dynamics to cellular homeostasis.
Materials and Methods
Patient
The index patient was referred to a national diagnostic and clin-
ical centre in Freiburg. Written informed consent was taken by
standard procedures for total genomic DNA extraction from
whole blood as well as skin and muscle biopsies.
Muscle biopsy analysis
A muscle sample was obtained from vastus lateralis and sub-
jected to routine histological and histochemical staining includ-
ing cytochrome c oxidase (COX), succinate dehydrogenase
(SDH), and sequential COX-SDH staining. Mitochondrial respira-
tory chain complex activities in skeletal muscle were measured
as described previously (35).
Molecular genetic studies
Mitochondrial DNA studies
Diagnostic testing for point mutations, deletions and depletion
of the mtDNA were performed by standard methods. Whole
exome sequencing (WES) was performed in the affected individ-
ual using Agilent SureSelect Human all Exon V4 and sequenced
on an Illumina HiSeq2000 platform with 100 bp paired-end
reads. Bioinfomatic prioritisation of genetic variants and segre-
gation analysis of the likely causal mutation was performed as
previously described (36). Variants identified by WES were con-
firmed by Sanger sequencing using custom-designed primers.
Quantitative real time PCR
RNA from control and patient fibroblasts was extracted using the
RNeasy mini kit (Qiagen, Manchester, UK) and cDNA was gener-
ated using High-Capacity cDNA Reverse Transcription Kit (Life
Technologies Ltd, Paisley, UK). Quantitative real time PCR was
performed using iTaqTM universal SYBRVR Green supermix (pri-
mers listed below) on a CFX96 TouchTM PCR system (BioRad,
Hertfordshire, UK). MIEF1 50-AGG ATG ACA ATG GCA TTG GC-30
(forward) and 50-CCG ATC GTA CAT CCG CTT AACT-30 (reverse);
for MIEF2, 50-GCA ACC AAT CCA CCA ACA GAA T-30 (forward) and
50-CCG GAA AAG GCG TTA AGT CAC-30 (reverse); b-Actin
50-GATGCAGAAGGAGATCACTGC-30 (forward) and 50-ACATCTGC
TGGAAGGTGGAC-30 (reverse); GAPDH 50-CTGACTTCAACAGCGA
CACC-30 (forward) and 5’-ATGAGGTCCACCACCCTGT-3’ (reverse).
Primary cell culture
Primary fibroblast cultures of the patient and controls were
obtained from the Newcastle Biobank. All studies were carried
out with informed consent of the patient and his parents and
were approved by institutional ethics review boards. Fibroblasts
were grown in high glucose Dulbecco’s modified Eagle’s medium
(DMEM) (Life Technologies Ltd, Paisley, UK) supplemented with
10% fetal bovine serum (Sigma-Aldrich, Dorset, UK).
Oxygen consumption rate
Oxygen consumption rate (OCR) in fibroblasts was measured with
a XF96 Extracellular Flux Analyser (Seahorse Bioscience, Agilent
Technologies, Cheshire, UK), as described previously (37). Each cell
line was seeded in 12 wells of a XF96-well cell culture microplate
(Seahorse Bioscience) at a density of 30103 cells/well in 80 ml of
DMEM and incubated for 24 h at 37C in 5% CO2 atmosphere. After
replacing the growth medium with 180uL of bicarbonate-free
DMEM (pre-warmed at 37C), cells were pre-incubated for 30 min
before starting the assay procedure. Oxygen consumption rate
(OCR), leaking respiration (LR), maximal capacity respiration
(MCR) and not electron transport chain respiration (NMR) were
determined by adding 1 lM oligomycin (LR), carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP) (MCR: 2 injections of
0.5 lM and 1 lM, respectively) and 1lM Rotenone/antimycin
(NMR), respectively (all Sigma-Aldrich, Dorset UK). The data were
corrected by the NMR and expressed as pmol of oxygen/min/mg
of protein. The quantity of protein was measured by Bradford
assay.
Immunoblotting
Total protein lysates and subcellular fractions were prepared
from muscle homogenates and primary fibroblasts from the
index patient and two controls. Protein samples were separated
on NuPAGETM NovexTM 4–12% Bis-Tris Protein Gels. Following
electrophoresis, the separated proteins were transferred onto
PVDF membrane using the iBlotVR 2 Dry Blotting System (Thermo
Fisher Scientific, UK) according to manufacturer’s instructions.
The membrane was then probed for the following proteins:
Total OXPHOS Rodent WB antibody cocktail (Abcam, ab110413),
Anti-DRP1 (ab56788), Anti-SMCR7L (MID51) (ab89944), Anti-
OPA1 (ab119685), Anti-Mitofusin 2 (ab56889), Anti-SMCR7
(MID49) (Proteintech, 16413–1-AP).
Analysis of mitochondrial matrix continuity and fusion event
frequency
Transfection of 1–2 lg of plasmid DNA was performed by
Lipofectamine 2000 (Invitrogen) following the provider’s recom-
mendations. We used mitochondrial matrix-targeting fluorescent
proteins, carrying the localization domain of cytochrome c oxi-
dase subunit VIII: mtDsRed (Takara Bio Inc.) and mtPA-GFP (38).
In vivo imaging assays were conducted in 0.25% BSA–
extracellular medium (121 mM NaCl, 5 mM NaHCO3, 4.7 mM
KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2 mM CaCl2, 10 mM glucose,
and 10 mM, Na-Hepes, pH 7.4, 35C). We used a Nikon Eclipse C2
confocal microscope, located at the Advanced Microscopy
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Facility UC, to perform time series of cells expressing mtPA-GFP
and mtDsRed, using 488-nm and 568-nm (or 561) laser lines,
every 5 s. The regions of interest were illuminated by a 408-nm
laser to photoconvert mtPAGFP. Continuity of mitochondria
was evaluated by following the spreading of PA-GFP from
the area of photoactivation, as previously described (39).
Mitochondrial fusion rate was evaluated as previously described
(40) and expressed as fusion events/run/min, where one run
represents three ROIs. Alternatively, MID49 rescue experiments
were tested by mitochondrial continuity applying FRAP assays.
Regions of 55 lm were illuminated by 408 and 488 nm lasers in
cells expressing mtDsRed. Human MID49-GFP cDNA construct
was kindly donated by Mike Ryan, Monash University (28). The
expression of the fusion protein was confirmed by immunoblot-
ting, using anti-GFP antibody (Clontech, #632592). Image analy-
sis was done in Fiji Image J.
Transmitted electron microscopy
Cultured fibroblasts were harvested within 24 after media
replacement. Pellets containing 8105 cells were fixed with 2.5%
glutaraldehyde and stained according to Csordas et al. (41).
Ultrathin sections were observed at a Phillips Tecnai 12 Biotwin
electron microscope, at the Microscopy Facility UC, Chile. The
morphometric analysis was performed by Fiji Image J.
Statistical analysis
Unpaired, 2-tailed t test was used to measure the level of statis-
tical significance. Data are presented as6 standard error of the
mean (SEM). A P-value of0.05 was considered significant.
Supplementary Material
Supplementary Material is available at HMG online.
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